Log in

Biogen Stock Price, Forecast & Analysis (NASDAQ:BIIB)

$281.89
-9.51 (-3.26 %)
(As of 11/14/2019 06:05 AM ET)
Today's Range
$280.95
Now: $281.89
$290.25
50-Day Range
$220.06
MA: $255.04
$300.18
52-Week Range
$215.77
Now: $281.89
$344.00
Volume1.93 million shs
Average Volume3.07 million shs
Market Capitalization$50.86 billion
P/E Ratio10.76
Dividend YieldN/A
Beta1.07
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.45 billion
Cash Flow$30.41 per share
Book Value$77.54 per share

Profitability

Net Income$4.43 billion

Miscellaneous

Employees7,800
Market Cap$50.86 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter.


Biogen (NASDAQ:BIIB) Frequently Asked Questions

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, October, 22nd. The biotechnology company reported $9.17 EPS for the quarter, beating analysts' consensus estimates of $8.27 by $0.90. The biotechnology company earned $3.60 billion during the quarter, compared to analysts' expectations of $3.53 billion. Biogen had a return on equity of 46.14% and a net margin of 37.91%. The firm's revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business posted $7.40 earnings per share. View Biogen's Earnings History.

When is Biogen's next earnings date?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Biogen.

What price target have analysts set for BIIB?

33 equities research analysts have issued 1-year price targets for Biogen's stock. Their forecasts range from $230.00 to $365.00. On average, they anticipate Biogen's stock price to reach $290.28 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Biogen.

What is the consensus analysts' recommendation for Biogen?

33 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 20 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

What are Wall Street analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:
  • 1. Cantor Fitzgerald analysts commented, ": Reiterate Neutral rating and $250 price target. Yesterday Novartis (NVS, NC) announced FDA approval of its oral S1P1 Mayzent (siponimod) in secondary progressive multiple sclerosis (SPMS), relapsing-remitting MS (RRMS), and clinically isolated syndrome using a priority voucher. We think this broad label is somewhat unexpected given that the pivotal study and regulatory filings were for SPMS patients, and a negative headline for competitors such as Biogen and possibly Celgene CELG, OW). With competitive efficacy and a cleaner label vs. NVS’ first gen S1P1 Gilenya, we think the key question is if and how quickly Mayzent can take share in RRMS post launch in early 2Q." (3/27/2019)
  • 2. HC Wainwright analysts commented, "Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (2/19/2019)

Has Biogen been receiving favorable news coverage?

Headlines about BIIB stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Biogen.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 4,080,000 shares, an increase of 23.6% from the September 30th total of 3,300,000 shares. Based on an average daily volume of 2,000,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 2.3% of the company's stock are sold short. View Biogen's Current Options Chain.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Celgene (CELG), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Boeing (BA) and Walt Disney (DIS).

Who are Biogen's key executives?

Biogen's management team includes the folowing people:
  • Mr. Michel Vounatsos, CEO & Director (Age 57)
  • Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 54)
  • Ms. Susan H. Alexander, Exec. VP, Chief Legal Officer & Sec. (Age 62)
  • Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 50)
  • Dr. Paul F. McKenzie, Exec. VP of Pharmaceutical Operations & Technology (Age 53)

Who are Biogen's major shareholders?

Biogen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.47%), Assenagon Asset Management S.A. (0.37%), Parnassus Investments CA (0.32%), California Public Employees Retirement System (0.27%), Massachusetts Financial Services Co. MA (0.25%) and Candriam Luxembourg S.C.A. (0.24%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Parnassus Investments CA, Candriam Luxembourg S.C.A., First Trust Advisors LP, State of New Jersey Common Pension Fund D, Robeco Institutional Asset Management B.V., Sector Gamma AS and Waverton Investment Management Ltd. View Insider Buying and Selling for Biogen.

Which institutional investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Banco Santander S.A., Railway Pension Investments Ltd, Alberta Investment Management Corp, Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Main Street Research LLC and California Public Employees Retirement System. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $281.89.

How big of a company is Biogen?

Biogen has a market capitalization of $50.86 billion and generates $13.45 billion in revenue each year. The biotechnology company earns $4.43 billion in net income (profit) each year or $26.20 on an earnings per share basis. Biogen employs 7,800 workers across the globe.View Additional Information About Biogen.

What is Biogen's official website?

The official website for Biogen is http://www.biogen.com/.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]


MarketBeat Community Rating for Biogen (NASDAQ BIIB)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,554 (Vote Outperform)
Underperform Votes:  955 (Vote Underperform)
Total Votes:  2,509
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Featured Article: After-Hours Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel